MRI Techniques for early-stage detection of cancer

Overview

About this study

The purpose of this study is to develop 7T MRI techniques for early-stage detection of cancer, using both hydrogen (1H) and deuterium (2H) imaging. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • aged 18 and older
  • ability to provide informed consent

Exclusion Criteria:

  • implanted active devices such as cardiac defibrillators/pacemakers, deep brain stimulators, vagus nerve stimulators, intrathecal pumps, cochlear implants
  • devices, or residual parts thereof left in the body such as cardiac pacer wires, which provide life assist, bone growth or pain management
  • structural support devices, screws, or wires in bone that are near the spinal cord or temperature sensitive organs
  • reconstructive metallic implants near the orbits
  • external devices, medicinal patches, piercings, jewelry, clothing or hair accessories (such as wigs, weaves and extensions) within to the radiofrequency coil that cannot be removed from the body
  • pregnancy
  • tattoos located within to the radiofrequency coil
  • metallic fragment in the eye
  • fever / elevated temperature
  • suffer from claustrophobia
  • for 2H deuterium-MRI exams, subjects who are in a current diabetic ketoacidosis or hyperosmolar hyperglycemic state will be excluded from participation in this study.
  • For 1H hydrogen MRI in subjects receiving a gadolinium-based contrast agent, subjects with a known allergy to these agents will be excluded from participation in this study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/14/2024. Questions regarding updates should be directed to the study team contact.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrew Fagan, Ph.D.

Contact us for the latest status

Contact information:

Kristin Fritz

(507) 293-0925

Yaggy.Kristin@mayo.edu

More information

Publications

Publications are currently not available